SC
NTLA icon

Slow Capital’s Intellia Therapeutics NTLA Stock Holding History

Slow Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-21,166
Closed -$289K – 162
2018
Q4 		$289K Buy
21,166
+9,235
+77% +$172K 0.14% 138
2018
Q3 		$341K Buy
11,931
+432
+4% +$12.6K 0.15% 135
2018
Q2 		$315K Sell
11,499
-4,562
-28% -$111K 0.16% 129
2018
Q1 		$339K Buy
16,061
+796
+5% +$19.6K 0.15% 132
2017
Q4 		$294K Buy
+15,265
New +$352K 0.15% 123

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Slow Capital's NTLA Position: Q1 2019 in Review

Slow Capital sold out of Intellia Therapeutics (NTLA) in Q1 2019, closing a stake of 21,166 shares — an estimated $289K sold.

Slow Capital first reported a position in NTLA in Q4 2017 and held it in 5 quarters. The position peaked at $341K in Q3 2018. 148 funds tracked by Wall St. Rank hold NTLA as of Q1 2019.

  • Slow Capital reported no remaining Intellia Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Slow Capital sold 21,166 Intellia Therapeutics shares in Q1 2019, an estimated $289K.
  • Slow Capital first reported a position in Intellia Therapeutics in Q4 2017 and held it in 5 quarters.
  • Slow Capital's Intellia Therapeutics position peaked at $341K in Q3 2018.
  • 148 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2019.

Based on Slow Capital's 13F filing for Q1 2019, filed 16 May 2019.